

A double-blind, placebo-controlled study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients with symptoms of overactive bladder

Submission date 15/02/2007	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 23/04/2007	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 22/05/2017	Condition category Urological and Genital Diseases	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Miss Sheryl Caswell

Contact details

Plethora Solutions
Lupus House
11-13 Macklin Street
London
United Kingdom
WC2B 5NH
+44 (0)20 7269 8630
sheryl.caswell@plethorasolutions.co.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

PSD506-OAB-005

Study information

Scientific Title

A double-blind, placebo-controlled study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients with symptoms of overactive bladder

Study objectives

Overactive bladder (OAB) is treated currently by anti-muscarinic drugs. Anti-muscarinic drugs may have cardiovascular side effects (such as tachycardia) and Central Nervous System (CNS) side effects. These side effects result from non-selective muscarinic blockade and from CNS penetration. PSD506 is a novel anti-muscarinic agent that is being developed for the treatment of OAB. This is the first study in patients suffering from OAB and will establish the efficacy of PSD506 in this condition as well as further assessing safety and tolerability in practice.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Central and South Bristol REC, 04/08/2006, ref: 06/Q2006/61

Study design

Multi-centre multi-national randomised double-blind placebo-controlled parallel-group study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied

Overactive bladder (OAB)

Interventions

Previously treated subjects will have a 4-week (28-day) washout period. All subjects will have a 1-week (7-day) run-in period.

PSD506 20 mg or matching placebo daily for 4 weeks (plus 4-week follow-up period).

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

PSD506 (antimuscarinic agent)

Primary outcome measure

Change from baseline in average number of micturitions per day (urinary frequency)

Secondary outcome measures

1. Change from baseline in average number of urge urinary incontinence episodes
2. Change from baseline in average number of urinary urgency episodes
3. Change from baseline in average volume voided per micturition
4. Change from baseline in scores on ICIQ-FLUTS SF or ICIQ-MLUTS SF
5. Change from baseline in score on ICIQ-OABqol

Overall study start date

01/07/2006

Completion date

31/12/2007

Eligibility

Key inclusion criteria

1. Age 18 years or over
 2. If female, must be surgically sterile or post-menopausal for at least a year and confirmed by a negative hormone panel (luteinizing hormone [LH], follicle stimulating hormone [FSH], 17β estradiol). Women who are receiving HRT at the time of screening may be defined as post-menopausal provided there is documentation in their medical history to confirm that they had stopped menstruating for one year before starting the HRT
 3. If male subject and partner is of childbearing potential must agree to use a secure form of contraception (e.g., pill, condom)
 4. Involuntary detrusor contraction associated with urgency during filling cystometry in the last 12 months prior to study entry
 5. Symptoms of OAB for at least 6 months prior to study entry. Subjects with concurrent Stress Urinary Incontinence (SUI) and OAB may be included provided the symptoms of OAB are dominant
 6. Willing and able to provide written informed consent
- Inclusion criteria at baseline:
7. Completed appropriate washout period (for previously treated subjects) and 7 days run-in period for all subjects (both treated subjects and treatment naïve subjects) prior to baseline visit

8. Have an average of 10 micturitions and at least one episode of urinary urgency per day (during the 7 days of run-in period)
9. Have an average of 7 episodes of urge urinary incontinence per week (during the 7 days of the run-in period)

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

100 subjects (50 subjects per group)

Key exclusion criteria

1. Female subject who is of childbearing potential
2. Uncontrolled hypertension, defined as mean systolic blood pressure [SBP] ≥ 160 mmHg or a diastolic blood pressure [DBP] ≥ 95 mmHg (after sitting for 5 minutes)
3. History of clinically significant hypotensive episodes or symptoms of fainting, dizziness or lightheadedness
4. Unstable cardiovascular disease, particularly coronary artery disease, arrhythmias, atrial tachycardia or congestive heart failure
5. Clinically significant central nervous system disease, including: Parkinsons disease, multiple sclerosis, transient ischemic attack, stroke, seizure disorder, depression or behavioral disturbances
6. History of peripheral vascular or cerebrovascular disease
7. History of narrow angle glaucoma or increased ocular pressure
8. Clinically significant bladder pathology (e.g., obstructive uropathy) or history of urinary retention
9. Clinically significant gastrointestinal disorder (e.g., gastroparesis, constipation, diarrhea, colitis, gastrointestinal tract obstruction, hiatal hernia with reflux oesophagitis, cholestasis)
10. History of clinically significant liver disease (e.g., hepatitis B)
11. Prohibited medications taken within the previous 2 weeks prior to baseline date (4 weeks for solifenacin)
12. Concomitant use of any agent that has a significant interaction with CYP3A4 or P glycoprotein (Pgp)
13. Clinically significant abnormalities in laboratory test results (including hepatic and renal panels, Complete Blood Count [CBC] and chemistry panel) at screening
14. Urinary tract infection within 6 weeks prior to baseline
15. Participation in an investigational drug or device study within 30 days prior to screening date
16. Known hypersensitivity to anti-cholinergic agents
17. Concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study; or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study. This would include, but is not limited to, cancer, alcoholism, drug dependency or abuse, or psychiatric disease

- 18. Unwillingness or inability to comply with the study protocol for any other reason
- 19. Unable to understand and complete the ICIQ-OABqol and ICIQ-FLUTS or ICIQ-MLUTS questionnaires or Micturition Diary
- 20. Any clinically significant abnormality on 12-lead ECG

Date of first enrolment

01/07/2006

Date of final enrolment

31/12/2007

Locations

Countries of recruitment

England

Germany

Ireland

United Kingdom

Study participating centre

Plethora Solutions

London

United Kingdom

WC2B 5NH

Sponsor information

Organisation

Plethora Solutions Ltd (UK)

Sponsor details

Lupus House

11-13 Macdklin Street

London

United Kingdom

WC2B 5NH

+44 (0)207 269 8630

mail@plethorasolutions.co.uk

Sponsor type

Industry

Website

<http://www.plethorasolutions.co.uk/index.php>

ROR

<https://ror.org/02y9vw172>

Funder(s)

Funder type

Industry

Funder Name

Plethora Solutions Ltd (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration